Mumbai, India, November 12, 2026: Lupin Limited, a prominent player in the global pharmaceutical industry, has announced the European launch of its biosimilar Ranibizumab, branded as Ranluspec™. The launch, executed in partnership with Sandoz, covers all European markets except Germany and follows the European Commission’s approval of the product in both vial and pre-filled syringe formats.
Ranibizumab is a recombinant humanised monoclonal antibody fragment designed to bind and inhibit vascular endothelial growth factor A. This biosimilar is indicated for the treatment of several retinal conditions, including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularisation. The introduction of Ranluspec™ is expected to enhance access to high-quality biologic treatments for patients suffering from these retinal diseases.
Thierry Volle, President of EMEA and Emerging Markets at Lupin, emphasised the strategic importance of the launch, stating that it aligns with Lupin’s goal to broaden the availability of high-quality biosimilars to patients with retinal and choroidal vascular diseases. Dr. Cyrus Karkaria, President of Lupin’s Biotech Business, highlighted the launch as a testament to the company’s growing capabilities in biosimilars, underscoring its commitment to addressing unmet medical needs and supporting sustainable healthcare systems.
Lupin Limited, headquartered in Mumbai, India, operates in over 100 markets worldwide, offering a diverse range of pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company maintains a strong presence in India and the United States across various therapeutic areas. With 15 manufacturing sites and six research centres globally, Lupin employs over 26,000 professionals dedicated to improving patient health outcomes.
The launch of Ranluspec™ in Europe marks a significant milestone for Lupin as it continues to expand its footprint in the biosimilars market. Analysts view this development as a positive step for the company, potentially enhancing its competitive position in the European market and contributing to its long-term growth strategy.
